This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
West Pharmaceutical (WST) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
West Pharmaceutical (WST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
West Pharmaceutical Services (WST) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 23.17% and 5.39%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Why West Pharmaceutical (WST) Might Surprise This Earnings Season
by Zacks Equity Research
West Pharmaceutical (WST) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
West Pharmaceutical Services (WST) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
West Pharmaceutical (WST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can West Pharmaceutical (WST) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
West Pharmaceutical (WST) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Invest in DaVita (DVA) Stock Right Now
by Zacks Equity Research
DaVita (DVA) continues to gain traction from strong international foothold, strategic buyout of dialysis centers and DaVita Kidney Care.
Here's Why You Should Retain Merit Medical (MMSI) Stock Now
by Zacks Equity Research
Merit Medical (MMSI) continues to benefit from growing product pipeline, strong R&D focus and strategic acquisitions.
Here's Why You Should Hold on to NextGen Healthcare Stock Now
by Zacks Equity Research
NextGen Healthcare (NXGN) continues to benefit from growing RCM and EHR markets, and robust demand for other NextGen solutions.
Here's Why You Should Retain Cerner (CERN) Stock for Now
by Zacks Equity Research
Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margin remains a woe.
NextGen's New Platform Set to Improve Patient Engagement
by Zacks Equity Research
The availability of NextGen's (NXGN) Patient Experience Platform is likely to enable high-quality healthcare and drive patient engagement.
Buy These 5 Low Leverage Stocks Amid Coronavirus Outbreak
by Zacks Equity Research
Higher debt financing is never desirable. So, an investor's portfolio should include stocks that are not highly leveraged.
Here's Why You Should Hold on to CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D. However, forex remains a woe.
Masimo Inks Deal With Imprivata, Improves Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) partnership with Imprivata is likely to boost patient outcomes through the integration of Imprivata Medical Device Access into Masimo's Hospital Automation solutions.
Here's Why You Should Retain HMS Holdings (HMSY) Stock Now
by Zacks Equity Research
HMS Holdings (HMSY) is gaining traction from growing PI and TPM analytical services.
Here's Why You Should Invest in Intuitive Surgical Stock Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base. However, stiff competition remains a woe.
Here's Why You Should Hold on to OPKO Health Stock for Now
by Zacks Equity Research
OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.
Here's Why You Should Invest in Integer Holdings Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.
MCK or WST: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MCK vs. WST: Which Stock Is the Better Value Option?
STERIS' (STE) Growth Picture Impressive Amid Rising Costs
by Zacks Equity Research
STERIS (STE) growing steadily on favorable underlying market trends, along with new product and service offerings.
Integra LifeSciences Grows Organically Amid Supply Issues
by Zacks Equity Research
Integra LifeSciences' (IART) Codman Specialty Surgical segment registers impressive organic growth in Q4.
Integer Holdings Acquires Inomec, Extends Global Foothold
by Zacks Equity Research
Integer Holdings' (ITGR) Inomec buyout is likely to boost R&D pipeline and also strengthen and expand global foothold.
Here's Why You Should Hold on to Cerner (CERN) Stock Now
by Zacks Equity Research
Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margins remain a woe.
Here's Why You Should Invest in Cardinal Health Stock Now
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment.
Medical Products Stock Q4 Earnings on Feb 13: DXCM, LH & More
by Urmimala Biswas
Strong foothold in the emerging markets so far widely contributes to some of the industry players' Q4 results.
Analysts Estimate West Pharmaceutical Services (WST) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.